PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523425-17-00

Enrollment

Registered

2026-05-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proteinuric kidney diseases

Brief summary

Relative change from baseline to Week 20 in 24-hr UPCR (mg/g)

Detailed description

Treatment response, defined as at least 25% relative reduction in 24-hr UPCR from baseline to Week 20, Treatment response, defined as at least 40% relative reduction in 24-hr UPCR from baseline to Week 20, Absolute change in eGFR in mL/min/1.73m2 (based on cystatin C) from baseline to Week 20

Interventions

DRUGPlacebo matching BI 764198

DRUGBI 764198

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Relative change from baseline to Week 20 in 24-hr UPCR (mg/g)	—

Secondary

Measure	Time frame
Treatment response, defined as at least 25% relative reduction in 24-hr UPCR from baseline to Week 20, Treatment response, defined as at least 40% relative reduction in 24-hr UPCR from baseline to Week 20, Absolute change in eGFR in mL/min/1.73m2 (based on cystatin C) from baseline to Week 20	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 21, 2026